Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Terminated 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 19CNS 6Lymphoid 4Gastrointestinal 4Tumor-Agnostic 3Other hematologic neoplasm 3Sarcoma 2Plasma cell 2Dermatologic 2Head & Neck 1Endocrine 1

Conditions

Cholangiocarcinoma 2Pancreatic Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × ceritinib × Gastrointestinal × Clear all
NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

University Health Network, Toronto

Phase 2 Not yet recruiting
25 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT02227940 2022-07-25

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Roswell Park Cancer Institute

Phase 1 Completed
38 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02374489 2018-04-05

A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

National Health Research Institutes, Taiwan

Phase 2 Terminated
9 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT02638909 2018-04-02

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Criterium, Inc.

Phase 2 Terminated
4 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡